Enrolling by invitationNo phase

A Digital Care Tool for Children and Teens With Type 1 Diabetes

Tests a digital tool for managing type 1 diabetes in children.

Key facts

Who runs it: University of British Columbia
Where: Vancouver, CanadaSee the site
Trial code: NCT07712809
Registry title: Intelligent Care Platform - Quasi-Experimental Trial
Status: Enrolling by invitation
People taking part: 80 people, planned
Started: 15 Apr 2026
Expected to end: 28 Feb 2028
Type of study: Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested: Digital Diabetes Care Platform
Record updated: 22 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and teens aged 3 to under 18 with type 1 diabetes who are cared for at the BC Children's Hospital diabetes clinic. Their caregivers and clinic staff can also join.

Age: Patients: 3 to under 18 years old. Caregivers and healthcare providers: no age range given.
Sex: All sexes can join.
Disease stage: Type 1 diabetes confirmed at least six weeks before joining, with at least two clinic visits expected during the study.
Earlier treatment: Must use Dexcom or a Glooko-compatible glucose monitor, plus multiple daily insulin injections or a Glooko-compatible insulin pump.

Main reasons for not taking part

Currently in foster care (older youth managing their own diabetes are assessed case by case)
Using a non-Health Canada-approved do-it-yourself looping system
In active treatment for a mental health diagnosis such as an eating disorder or depression

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

A. Healthcare providers (HCP) including endocrinologists, endocrinology fellows (trainees), nursing staff and allied health staff (registered dietitians, social worker), currently providing care to pediatric patients in the Diabetes Clinic in the Division of Endocrinology at BC Children's Hospital (BCCH) will be eligible to participate
Patient participants and their caregivers will be recruited based on specific inclusion criteria to ensure the study population aligns with the research objectives. Eligible patients:
must currently be under the care of the clinic and have their endocrinologist participating in the study
must be between 3 and <18 years old at the time of recruitment
require a confirmed diagnosis of type 1 diabetes at least six weeks before recruitment, with at least two clinical appointments anticipated during the study period
must be using specific glucose monitoring devices, either Dexcom or that are compatible with Glooko (refer to Glooko website link: https://support.glooko.com/hc/en-us/articles/4402302889491-Compatibility-Reference-All-Uploading-Methods) and either use basal-bolus multiple daily injection (MDI) or a Glooko compatible insulin pump for their insulin delivery method as part of their diabetes management
Caregivers, defined as the primary individual involved in daily diabetes management (e.g., parent or legal guardian), must also be enrolled, understand verbal and written English, and be able to engage with the study materials
As the sharing of data from diabetes devices with the platform is enabled by a connection with a patient's or parent's Glooko account, participants must also either have a Glooko account or be willing to sign-up for a Glooko to be eligible to participate so that this data can be visualized within the Careteam platform

Who cannot take part

Patients will be excluded from participation if they are:; Currently in foster care because foster parents/guardians may change without the knowledge of the clinical team, making training of new foster parents/guardians on the platform a challenge. Participation for older youth in foster care who are independently managing their diabetes and have capacity to consent to participate in the study will be assessed for inclusion to participate on a case-by-case basis and in collaboration with the clinical team; Using a non-Health Canada-approved "looping do-it-yourself" system for diabetes management; Undergoing active treatment for a mental health diagnosis such as an eating disorder or depression; These exclusions are designed to ensure the safety and appropriateness of the intervention for the study population

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 3 and 18 years old?

Where in Canada

BC Children ' s HospitalVancouver, CanadaNo longer taking part

About the trial

What the trial wants to find out

This study will measure the implementation and effectiveness of an intervention, the use of a digital health tool, Haibu Diabetes, for the management of pediatric type 1 diabetes (T1D), on clinical outcomes. The investigators will use both quantitative (i.e., surveys) and qualitative (i.e., interviews) methods to assess implementation. To measure effectiveness, the investigators will compare users of the technology to a matched comparison group of non-users on relevant clinical outcomes using clinical data. Overall, the investigators hope to understand whether use of this digital tool improves clinical outcomes while also considering factors that affect implementation and clinical operations.

The 2 groups in the trial

Haibu Diabetes usersTreatment being tested
This group will use Haibu Diabetes throughout the trial both independently and in collaboration with their healthcare providers.
Treatment: Digital Diabetes Care Platform
Propensity score matched control groupNo study treatment, for comparison
A matched sample will be used to form a comparison group of non-users. These data will be obtained from a clinical registry, the BC Pediatric Diabetes Registry.